Ipsen (IPSEY) News Today $29.38 +0.62 (+2.16%) As of 03/28/2025 10:09 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Ipsen (OTCMKTS:IPSEY) Share Price Crosses Above 200-Day Moving Average - Here's What HappenedIpsen (OTCMKTS:IPSEY) Share Price Crosses Above 200 Day Moving Average - Here's What HappenedMarch 20, 2025 | marketbeat.comIpsen Pharma: Ipsen announces issuance of €500 million inaugural Rated Public BondMarch 19, 2025 | finanznachrichten.deIpsen announces issuance of €500 million inaugural Rated Public BondMarch 19, 2025 | finance.yahoo.comIpsen S.A. (OTCMKTS:IPSEY) Short Interest Down 80.0% in FebruaryIpsen S.A. (OTCMKTS:IPSEY - Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 100 shares, a drop of 80.0% from the February 13th total of 500 shares. Based on an average daily trading volume, of 1,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company's stock are short sold.March 13, 2025 | marketbeat.comIpsen appoints Olivia Brown as Executive Vice-President, Global Head of NeurotoxinsMarch 12, 2025 | markets.businessinsider.comIpsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capitalMarch 7, 2025 | uk.finance.yahoo.comIpsen (OTCMKTS:IPSEY) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedIpsen (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average - Here's What HappenedMarch 7, 2025 | marketbeat.comMarengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with IpsenMarch 3, 2025 | finance.yahoo.comShort Interest in Ipsen S.A. (OTCMKTS:IPSEY) Grows By 400.0%Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 500 shares, a growth of 400.0% from the January 31st total of 100 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is presently 0.4 days.February 28, 2025 | marketbeat.comBarclays Reaffirms Their Hold Rating on Ipsen (0MH6)February 18, 2025 | markets.businessinsider.comUBS Sticks to Their Buy Rating for Ipsen (0MH6)February 14, 2025 | markets.businessinsider.comIpsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...February 14, 2025 | finance.yahoo.comIpsen (OTCMKTS:IPSEY) Stock Crosses Above Two Hundred Day Moving Average - Here's What HappenedIpsen (OTCMKTS:IPSEY) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?February 14, 2025 | marketbeat.comIpsen targets 5%+ sales growth and 30%+ margin for 2025 amid strong pipeline and launchesFebruary 13, 2025 | msn.comIpsen S.A. (IPSEY) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comIpsen stock falls following mixed Q4 resultsFebruary 13, 2025 | msn.comIpsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025February 13, 2025 | markets.businessinsider.comIpsen (0MH6) Gets a Hold from Kepler CapitalFebruary 13, 2025 | markets.businessinsider.comMorgan Stanley cuts Ipsen stock rating to underweight, target to EUR120February 12, 2025 | msn.comIpsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capitalFebruary 6, 2025 | uk.finance.yahoo.comIpsen (OTCMKTS:IPSEY) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyIpsen (OTCMKTS:IPSEY) Stock Passes Above 200-Day Moving Average - Here's WhyFebruary 6, 2025 | marketbeat.comHamburg Sea Devils sign Jonathan IpsenFebruary 5, 2025 | msn.comFormer exec at drugmaker Ipsen sentenced to prison for insider tradingJanuary 30, 2025 | reuters.comJefferies Reaffirms Their Hold Rating on Ipsen (0MH6)January 30, 2025 | markets.businessinsider.comBarclays Remains a Hold on Ipsen (0MH6)January 21, 2025 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Shares Cross Above 200-Day Moving Average - Here's WhyIpsen (OTCMKTS:IPSEY) Shares Cross Above 200-Day Moving Average - Here's What HappenedJanuary 14, 2025 | marketbeat.comIpsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncologyDecember 3, 2024 | markets.businessinsider.comIpsen And Biomunex Reach Licensing Agreement For MAIT Cell Engager In Immuno-OncologyDecember 3, 2024 | markets.businessinsider.comBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSNovember 18, 2024 | uk.finance.yahoo.comIpsen Pharma: Bylvay (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSNovember 18, 2024 | finanznachrichten.deIpsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusNovember 16, 2024 | finanznachrichten.deIqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusNovember 16, 2024 | finance.yahoo.comIpsen's elafibranor recommended for use in patients with rare liver diseaseOctober 27, 2024 | msn.comIpsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidanceOctober 23, 2024 | uk.finance.yahoo.comIpsen Q3 Sales Increase; Lifts FY24 Outlook - Quick FactsOctober 23, 2024 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?Ipsen (OTCMKTS:IPSEY) Stock Crosses Above Two Hundred Day Moving Average - What's Next?October 22, 2024 | marketbeat.comIpsen Pharma: Ipsen receives its second Shingo Prize for operational excellenceOctober 14, 2024 | finanznachrichten.deIpsen receives its second Shingo Prize for operational excellenceOctober 14, 2024 | finance.yahoo.comIpsen Pharma: Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseSeptember 23, 2024 | finanznachrichten.deIpsen: European Commission Approves Kayfanda - Quick FactsSeptember 23, 2024 | markets.businessinsider.comIpsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseSeptember 23, 2024 | finance.yahoo.comIpsen Pharma: Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeSeptember 20, 2024 | finanznachrichten.deIpsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeSeptember 20, 2024 | markets.businessinsider.comIpsen: European Commission Grants Conditional Marketing Authorization For IqirvoSeptember 20, 2024 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Upgraded by Royal Bank of Canada to "Moderate Buy"Royal Bank of Canada upgraded shares of Ipsen from a "hold" rating to a "moderate buy" rating in a report on Monday.September 20, 2024 | marketbeat.comIpsen (0MH6) Receives a Buy from Kepler CapitalSeptember 18, 2024 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Shares Cross Above 200-Day Moving Average of $30.20Ipsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average of $30.20September 17, 2024 | marketbeat.comIpsen Pharma: Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumorsSeptember 16, 2024 | finanznachrichten.deFinal results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumorsSeptember 16, 2024 | finance.yahoo.comEmployee of French drugmaker Ipsen to plead guilty to US insider tradingSeptember 11, 2024 | reuters.com Remove Ads Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Media Mentions By Week IPSEY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSEY News Sentiment▼0.000.82▲Average Medical News Sentiment IPSEY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSEY Articles This Week▼01▲IPSEY Articles Average Week Remove Ads Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEXX Laboratories News Lantheus News QuidelOrtho News Neogen News Celldex Therapeutics News Intellia Therapeutics News Myriad Genetics News Oruka Therapeutics News Alpha Teknova News Achieve Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPSEY) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ipsen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
